Your browser doesn't support javascript.
loading
The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial.
Hollingworth, Milo; Woodhouse, Lisa J; Law, Zhe K; Ali, Azlinawati; Krishnan, Kailash; Dineen, Robert A; Christensen, Hanne; England, Timothy J; Roffe, Christine; Werring, David; Peters, Nils; Ciccone, Alfonso; Robinson, Thompson; Czlonkowska, Anna; Bereczki, Dániel; Egea-Guerrero, Juan José; Ozturk, Serefnur; Bath, Philip M; Sprigg, Nikola.
Afiliação
  • Hollingworth M; Department of Neurosurgery, Nottingham University Hospitals, Nottingham , UK.
  • Woodhouse LJ; Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
  • Law ZK; Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
  • Ali A; Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
  • Krishnan K; Department of Medicine, Faculty of Medicine, National University of Malaysia, Kuala Lumpur , Malaysia.
  • Dineen RA; Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
  • Christensen H; Faculty of Health Sciences, School of Medical Imaging, University of Sultan Zainal Abidin, Kuala Nerus , Malaysia.
  • England TJ; Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
  • Roffe C; Stroke, Department of Acute Medicine, Nottingham University Hospitals, Nottingham , UK.
  • Werring D; Radiological Sciences, Mental Health and Clinical Neuroscience, University of Nottingham, Nottingham , UK.
  • Peters N; NIHR Nottingham Biomedical Research Centre, Nottingham , UK.
  • Ciccone A; Department of Neurology, Copenhagen University Hospital, Bispebjerg , Denmark.
  • Robinson T; Stroke Trials Unit, Mental Health & Clinical Neurosciences, Queen's Medical Centre, School of Medicine, University of Nottingham, Nottingham , UK.
  • Czlonkowska A; Stroke, Royal Derby Hospital, University Hospitals of Derby and Burton, Derby , UK.
  • Bereczki D; Stroke Research, School of Medicine, Keele University, Newcastle under Lyme , UK.
  • Egea-Guerrero JJ; Stroke Research Centre, Brain Repair & Rehabilitation, UCL Queen Square Institute of Neurology, London , UK.
  • Ozturk S; Stroke Center and Department of Neurology, University Hospital Basel, University of Basel, Basel , Switzerland.
  • Bath PM; Azienda Socio Sanitaria Territoriale di Mantova, Mantova , Italy.
  • Sprigg N; College of Life Sciences, University of Leicester, Leicester , UK.
Neurosurgery ; 95(3): 605-616, 2024 Sep 01.
Article em En | MEDLINE | ID: mdl-38785451
ABSTRACT
BACKGROUND AND

OBJECTIVES:

An important proportion of patients with spontaneous intracerebral hemorrhage (ICH) undergo neurosurgical intervention to reduce mass effect from large hematomas and control the complications of bleeding, including hematoma expansion and hydrocephalus. The Tranexamic acid (TXA) for hyperacute primary IntraCerebral Hemorrhage (TICH-2) trial demonstrated that tranexamic acid (TXA) reduces the risk of hematoma expansion. We hypothesized that TXA would reduce the frequency of surgery (primary outcome) and improve functional outcome at 90 days in surgically treated patients in the TICH-2 data set.

METHODS:

Participants enrolled in TICH-2 were randomized to placebo or TXA. Participants randomized to either TXA or placebo were analyzed for whether they received neurosurgery within 7 days and their characteristics, outcomes, hematoma volumes (HVs) were compared. Characteristics and outcomes of participants who received surgery were also compared with those who did not.

RESULTS:

Neurosurgery was performed in 5.2% of participants (121/2325), including craniotomy (57%), hematoma drainage (33%), and external ventricular drainage (21%). The number of patients receiving surgery who received TXA vs placebo were similar at 4.9% (57/1153) and 5.5% (64/1163), respectively (odds ratio [OR] 0.893; 95% CI 0.619-1.289; P -value = .545). TXA did not improve outcome compared with placebo in either surgically treated participants (OR 0.79; 95% CI 0.30-2.09; P = .64) or those undergoing hematoma evacuation by drainage or craniotomy (OR 1.19 95% 0.51-2.78; P -value = .69). Postoperative HV was not reduced by TXA (mean difference -8.97 95% CI -23.77, 5.82; P -value = .45).

CONCLUSION:

TXA was not associated with less neurosurgical intervention, reduced HV, or improved outcomes after surgery.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Tranexâmico / Hemorragia Cerebral / Procedimentos Neurocirúrgicos / Hematoma / Antifibrinolíticos Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Tranexâmico / Hemorragia Cerebral / Procedimentos Neurocirúrgicos / Hematoma / Antifibrinolíticos Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article